Acorn Financial Advisory Services Inc. ADV acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 7,282 shares of the biopharmaceutical company’s stock, valued at approximately $286,000.
Other institutional investors also recently bought and sold shares of the company. 1 North Wealth Services LLC bought a new position in shares of Pfizer during the 3rd quarter valued at $29,000. Bourgeon Capital Management LLC bought a new position in shares of Pfizer during the 3rd quarter valued at $32,000. Salomon & Ludwin LLC grew its holdings in shares of Pfizer by 362.7% during the 3rd quarter. Salomon & Ludwin LLC now owns 893 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 700 shares during the last quarter. B & T Capital Management DBA Alpha Capital Management bought a new position in shares of Pfizer during the 3rd quarter valued at $36,000. Finally, TFO TDC LLC bought a new position in shares of Pfizer during the 4th quarter valued at $37,000. Hedge funds and other institutional investors own 70.19% of the company’s stock.
Shares of Pfizer stock opened at $40.16 on Tuesday. The firm has a market cap of $220.37 billion, a PE ratio of 14.04, a price-to-earnings-growth ratio of 4.16 and a beta of 0.65. Pfizer Inc. has a 12-month low of $33.97 and a 12-month high of $44.56. The company has a quick ratio of 0.68, a current ratio of 0.90 and a debt-to-equity ratio of 0.55. The company’s fifty day simple moving average is $39.37 and its two-hundred day simple moving average is $37.97.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.13. Pfizer had a net margin of 30.57% and a return on equity of 28.10%. The firm had revenue of $12.68 billion during the quarter, compared to analysts’ expectations of $12.37 billion. During the same period last year, the company posted $0.78 EPS. The company’s quarterly revenue was down 4.6% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 31st will be given a $0.38 dividend. This represents a $1.52 annualized dividend and a dividend yield of 3.78%. This is a boost from Pfizer’s previous quarterly dividend of $0.36. The ex-dividend date of this dividend is Thursday, January 30th. Pfizer’s dividend payout ratio (DPR) is currently 48.00%.
A number of brokerages have issued reports on PFE. ValuEngine raised shares of Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Pfizer in a report on Tuesday, October 29th. Royal Bank of Canada began coverage on shares of Pfizer in a report on Monday, January 6th. They issued an “outperform” rating and a $46.00 price target on the stock. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price target on the stock in a report on Tuesday, October 1st. Finally, Bank of America began coverage on shares of Pfizer in a report on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 price target on the stock. Nine equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $43.41.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Article: Google Finance Portfolio
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.